326
Participants
Start Date
December 31, 2008
Primary Completion Date
March 31, 2010
Study Completion Date
April 30, 2010
125 µg Ocriplasmin
125µg ocriplasmin intravitreal injection
Placebo
Placebo intravitreal injection
New York Eye and Ear Infirmary, New York
Columbia University - Harkness Eye Institute, New York
Retina Vitreous Surgeons of Central NY, New York
Allegheny Ophthalmic & Orbital Associates, PC, Pittsburgh
Pennsylvania Retina Specialists, P.C., Camp Hill
National Retina Institute, Towson
Wake Forest University Eye Center, Winston-Salem
Duke Eye Center, Durham
Caroline Eye Associates, Southern Pines
Southeast Retina Center, PC, Augusta
University of Miami-Bascom Palmer Eye Institute- Palm Beach, Palm Beach
Center for Retina and Macular Disease, Winter Haven
National Ophthalmologic Research Institute, Fort Meyers
Sarasota Retina Institute, Sarasota
Souteastern Retina Associates, Kingsport
Retina Association of Cleveland, Lakewood
Midwest Eye Institute, Indianapolis
Associated Retina Consultants, Royal Oak
University of Michigan-Kellogg Eye Center, Ann Arbor
Vitreo-Retinal Associates, Grand Rapids
Vitroretinal Surgery PA, Minneapolis
Rush University Med. Ctr, Chicago
Vitroretinal Consultants, Houston
Retinal Consultants of San Antonio, San Antonio
Valley Retina Institute, P.A., McAllen
Austin Retina Associates, Austin
Colorado Retina Associates, PC, Denver
Retinal Consultants of AZ, Phoenix
Assocaited Retina Consultants, Ltd., Phoenix
Retina Centers, P.C., Tucson
Jules Stein Eye Institute/UCLA, Los Angeles
Retina Vitreous Associate Medical Group, Beverly Hills
Southern California Desert Retina Consultants, Palm Springs
VMR Institute, Huntington Beach
Retinal Consultants Medical Group, Sacramento
Rocky Mountain Lions Eye Institute, Aurora
Univ. Of Kentuck/Kentucky-Clinic/Dept of Ophthal & VS, Lexington
Maine Vitreoretinal Consultants, LLC, PA, Bangor
Kresge Eye Institute, Detroit
Retina Vitreous Centre, PA, New Brunswick
Retina Association of NJ, Teaneck
Lead Sponsor
ThromboGenics
INDUSTRY